TI-1007

N/A

Report date: 2024/11/13 20:00:43

Base Information

Drug NameTI-1007

Drug Alias NameTriCAR-T-CD19 adoptive immunotherapyCAR-T/CD19TI-1007

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsImmunologic cytotoxicityT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesTianjin Timmune Biotech Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTianjin Timmune Biotech Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A